1.1. Program Leaders. Co-Leader (Clinical Research) - Claudine Isaacs, MD. Dr. Claudine Isaacs Is an Associate Professor in the Departments of Medicine and Oncology; she assumed the position of the Breast Cancer Program Clinical Co-Leader in 2001. Dr. Isaacs received her medical degree (MDCM) and residency training at McGill University (Canada). Following fellowship training in the Division of Medical Oncology at Georgetown University, she joined the faculty in the Department of Medicine (Division of Hematology and Medical Oncology) and she is now also a member in the Department of Oncology. Her research interests include genetic testing, breast cancer treatment, and prevention strategies for women at high risk of breast cancer. In addition, she has served as the PI of a variety of clinical trials In breast cancer screening and prevention, early-stage disease, and metastatic disease. Dr. Isaacs has been a longstanding member of the BC Program and serves as Co-Director of the Jess and Mildred Fisher Center for Familial Cancer Research of the Lombardi Comprehensive Cancer Center. She recently co-chaired a multi-institutional study of breast screening in genetically high-risk women and is currently conducting a Phase 2 trial of sorafenib and anastrazole in metastatic breast cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA051008-19
Application #
8375510
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
2014-04-30
Budget Start
2012-05-01
Budget End
2013-04-30
Support Year
19
Fiscal Year
2012
Total Cost
$42,006
Indirect Cost
Name
Georgetown University
Department
Type
DUNS #
049515844
City
Washington
State
DC
Country
United States
Zip Code
20057
O'Neill, Suzanne C; Taylor, Kathryn L; Clapp, Jonathan et al. (2018) Multilevel Influences on Patient-Oncologist Communication about Genomic Test Results: Oncologist Perspectives. J Health Commun 23:679-686
Kim, Sang-Soo; Harford, Joe B; Moghe, Manish et al. (2018) Targeted nanocomplex carrying siRNA against MALAT1 sensitizes glioblastoma to temozolomide. Nucleic Acids Res 46:1424-1440
Laiakis, Evagelia C; Mak, Tytus D; Strawn, Steven J et al. (2018) Global metabolomic responses in urine from atm deficient mice in response to LD50/30 gamma irradiation doses. Environ Mol Mutagen 59:576-585
Wärri, Anni; Cook, Katherine L; Hu, Rong et al. (2018) Autophagy and unfolded protein response (UPR) regulate mammary gland involution by restraining apoptosis-driven irreversible changes. Cell Death Discov 4:40
Wallington, Sherrie; Oppong, Bridget; Dash, Chiranjeev et al. (2018) A Community-Based Outreach Navigator Approach to Establishing Partnerships for a Safety Net Mammography Screening Center. J Cancer Educ 33:782-787
Fu, Ying; Silverstein, Shana; McCutcheon, Justine N et al. (2018) An endogenous DNA adduct as a prognostic biomarker for hepatocarcinogenesis and its prevention by Theaphenon E in mice. Hepatology 67:159-170
Pohlmann, Paula R; Isaacs, Claudine (2018) Extended Adjuvant Endocrine Therapy for Postmenopausal Women: Treating Many to Benefit a Few. J Natl Cancer Inst 110:
Xiao, David; Zheng, Chaoyi; Jindal, Manila et al. (2018) Medicaid Expansion and Disparity Reduction in Surgical Cancer Care at High-Quality Hospitals. J Am Coll Surg 226:22-29
Stires, Hillary; Heckler, Mary M; Fu, Xiaoyong et al. (2018) Integrated molecular analysis of Tamoxifen-resistant invasive lobular breast cancer cells identifies MAPK and GRM/mGluR signaling as therapeutic vulnerabilities. Mol Cell Endocrinol 471:105-117
Zheng, Wenjie; Wu, Xiuhua; Goudarzi, Maryam et al. (2018) Metabolomic alterations associated with Behçet's disease. Arthritis Res Ther 20:214

Showing the most recent 10 out of 1120 publications